scholarly journals Anti-Inflammatory and Antioxidant Effects of Kelong-Capsule on Testosterone-Induced Benign Prostatic Hyperplasia in Rats

2018 ◽  
Vol 2018 ◽  
pp. 1-8
Author(s):  
Ling Zhang ◽  
Xin-Rong Fan ◽  
Hui Xie ◽  
Qing-Hu He ◽  
Yu-Song Nie ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Common Disease ◽  
Related Factor ◽  
Group Model ◽  
Model Group ◽  
Male Population ◽  
Treatment Groups ◽  
Ageing Male ◽  
Antioxidant Effects

Benign prostatic hyperplasia (BPH) is a common disease in the current ageing male population. This research aims to study the effects of Kelong-Capsules (KLC) on testosterone-induced BPH. Thirty rats were randomly divided into normal group, model group, and three treatment groups. Three treatment groups were given KLC (3.6 g/kg), KLC (7.2 g/kg), and finasteride (0.9 mg/kg), respectively, for 28 days after establishing the animal model. The BPH rat models were evaluated by Traditional Chinese Medicine (TCM) symptoms and prostate index (PI). Results indicated that three treatment groups all alleviated the pathological changes of prostate and kidney at different levels. Compared with the model group, the PI of the groups treated with KLC (7.2 g/kg) and finasteride decreased significantly. The expressions of NF-E2 related factor 2 (Nrf-2) and quinine oxidoreductase (NQO1) in the group treated with KLC (3.6 g/kg) increased markedly (p<0.01). The cyclooxygenase-2 (COX-2) protein expression of the group treated with KLC (7.2 g/kg) was increased (p<0.01). In conclusion, KLC could obviously inhibit the growth of prostate, and KLC (3.6 g/kg) could promote the expressions of Nrf2 and NQO1.

scholarly journals Histoprotective Effect of Essential Oil from Citrus aurantifolia in Testosterone-Induced Benign Prostatic Hyperplasia Rat

2019 ◽  
Vol 2019 ◽  
pp. 1-14
Author(s):  
Desmond O. Acheampong ◽  
Isaac K. Barffour ◽  
Alex Boye ◽  
Ernest A. Asiamah ◽  
Francis A. Armah ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Essential Oil ◽  
Prostate Gland ◽  
Prostatic Hyperplasia ◽  
Male Rats ◽  
Model Group ◽  
Sprague Dawley ◽  
Citrus Aurantifolia ◽  
Treatment Groups ◽  
Total Antioxidant

Background. Benign prostatic hyperplasia (BPH) is a common urological disorder reported among ageing men. Objective. The study assessed histoprotective effect of lime essential oil (LEO) in a rat model of testosterone-induced benign prostatic hyperplasia (BPH) and evaluated its ability to reverse testosterone-mediated changes in the testis, kidney, and liver. Materials and Methods. Adult Sprague Dawley (aged 12 weeks, 240–390 g) male rats were intramuscularly injected with testosterone enanthate (TE) (10 mg/kg) reconstituted in olive oil for ten days to establish benign prostatic hyperplasia (serum PSA level ≥ 1.24 ng/ml) in. After confirmation of BPH (sustained serum PSA level ≥ 1.24 ng/ml), rats in all groups (LEO: 30, 100, and 300 mg/kg, po, n = 6; finasteride: 15 mg/kg, po, n = 6) except model (BPH without treatment) and sham (no BPH and no treatment) groups were treated for 21 days. At the end of treatment, rats were anesthetised and blood was collected via cardiac puncture to determine serum PSA and total antioxidant capacity (TAC) levels. The prostate gland, testis, kidney, and liver were harvested, weighed, histologically processed and stained with H&E. Results. LEO- and finasteride-treated groups recorded lesser mean prostatic weights relative to their model group. Baseline mean serum PSA level of LEO- and finasteride-treated groups reduced significantly (p<0.05) relative to model group. Serum TAC levels were also higher in LEO- and finasteride-treated groups relative to model group. LEO-treated groups had less thickened glandular epithelium, smaller acini, fewer prostatic secretions and more fibromuscular stroma relative to model group. LEO and finasteride treatment produced improved histomorphological characteristics of testis, kidney, and liver compared to model group. Conclusion. By the current results, Citrus aurantifolia LEO may possess active agents that can be explored for translational medicine against BPH.

scholarly journals Evaluation of Juniperus communis L. seed extract on benign prostatic hyperplasia induced in male Wistar rats

2021 ◽  
Vol 27 (1) ◽  
Author(s):  
Fatemeh Akbari ◽  
Mohammad Azadbakht ◽  
Kanu Megha ◽  
Ayat Dashti ◽  
Lale Vahedi ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Wistar Rats ◽  
Histopathological Examination ◽  
Seed Extract ◽  
Prostatic Hyperplasia ◽  
Vehicle Group ◽  
Common Disease ◽  
Therapeutic Effects ◽  
Juniperus Communis ◽  
Male Wistar Rats

Abstract Background Benign prostatic hyperplasia (BPH) is a common disease which causes various health problems for elderly men such as urinary retention, recurring urinary tract infection and bladder stones. The aim of this study is to evaluate the therapeutic effects of Juniperus communis L. seed extract (JCS) on BPH in male Wistar rats. Methods To this end, 30 rats were divided into 5 groups (N = 6): group 1 (vehicle), group 2 (disease control), group 3 (standard medicine; 10 mg/kg finasteride), and groups 4 and 5 were treated with 300 mg/kg and 600 mg/kg of the hydroalcoholic JCS seed extract, respectively. Groups 2, 3, 4 and 5 received testosterone enanthate to induce prostatic hyperplasia. At the end of experimental period (28 days), prostate glands were cut off under anesthesia. Histopathological examination was done and biochemical parameters such as Malondialdehyde, Glutathione and protein carbonyl were also measured. Their body weights were also observed during the study. At the end of the experiment, prostate weights and prostate specific antigen (PSA) levels were measured. Prostate index, inhibition prostate weight and inhibition prostate index were also calculated. Results Both histopathological examination and biochemical parameter results showed significant improvements in rats treated with finasteride and 600 mg/kg JCS extract (p < 0.01). In addition, PSA levels showed significant decrease in comparison with the disease group. But acute toxicity test indicated that using JCS extract resulted in an increase in liver enzymes (ALP, LDH, SGOT, SGPT). As a result, the extract should be used with caution. Conclusions Oral administration of JCS extract is effective on preventing testosterone-induced benign prostatic hyperplasia.

scholarly journals Antiproliferative and Antioxidant Effects of Withania coagulans Extract on Benign Prostatic Hyperplasia in Rats

2016 ◽  
Vol 8 (1) ◽  
Author(s):  
Maryam Sarbishegi ◽  
Mohaddeseh Khani ◽  
Saeedeh Salimi ◽  
Mohharam Valizadeh ◽  
Fereydoon Sargolzaei Aval
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Withania Coagulans ◽  
Antioxidant Effects

Prevention system and medical support for patients with benign prostatic hyperplasia

2021 ◽  
pp. 18-27
Author(s):  
Egor Aleksandrovich Perevezentsev ◽  
Nadezhda Ilyinichna Gurvich ◽  
Tatyana Andreevna Agapova
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Support System ◽  
Primary Care Physicians ◽  
Prostatic Hyperplasia ◽  
Weak Continuity ◽  
Medical Support ◽  
Male Population ◽  
Minimally Invasive Surgical ◽  
Surgical Methods ◽  
High Level

The article presents an analysis of the current state of the prevention and medical support system for patients with benign prostatic hyperplasia. The urgency of the problem is determined by the significant influence of benign prostatic hyperplasia (BPH) on the quality of life of the male population. The identified shortcomings of the prevention and medical support system (low rates of referral and awareness of the population, insufficiently high level of urological training of primary care physicians, weak continuity between outpatient clinics, etc.) indicate the need for changes in the system of urological care for patients with BPH. The combined use of effective preventive measures and minimally invasive surgical methods for treating BPH increases the efficiency of outpatient and inpatient institutions.

scholarly journals The aging male population and medical care for benign prostatic hyperplasia in Canada

2013 ◽  
Vol 4 (2) ◽  
pp. 123
Author(s):  
Nigel S. B. Rawson ◽  
Fred Saad
Keyword(s):  
Primary Care ◽  
Benign Prostatic Hyperplasia ◽  
Nous Avons ◽  
Medical Care ◽  
Primary Care Physicians ◽  
Prostatic Hyperplasia ◽  
Population Projections ◽  
Prise En Charge ◽  
Male Population ◽  
Statistics Canada

Background: The male Canadian population is aging and more menwill be seeking medical care for benign prostatic hyperplasia (BPH).We examined the projected increase in older Canadian males between2005 and 2018 to evaluate urologic health-care needs.Methods: We used Statistics Canada population projections toderive predictions of the male population aged 50 or more from2005 to 2018 and results from the Olmsted County Study of UrinarySymptoms to estimate numbers of males aged ≥50 with moderateto severe lower urinary tract symptoms (msLUTS) in the sameperiod. Data from the Canadian Institute for Health Informationwere used to estimate the number of urologists in 2018.Results: The number of Canadian men aged ≥50 is projected torise between 2005 and 2018 by 39.5% and the number withmsLUTS by 41.3%. However, the number of practicing urologistsin Canada in 2018 is likely to be similar to the 584 practicing in2007. An increase in the number of urologists proportional to theincrease in men aged ≥50 with msLUTS would require 799 urologistsin 2018.Interpretation: Little opportunity exists to expand the number of traineesin urology. Other alternatives must be sought to deal with increasednumbers of older men with msLUTS. Initial management of BPHhas moved towards being a responsibility of primary care physicians,but they appear to view BPH as a quality-of-life issue. It iscrucial that urologists work closely with primary care physicians toensure that the management of LUTS progression is optimized.Introduction : La population masculine canadienne vieillit, et deplus en plus d’hommes consulteront un médecin en raison d’unehyperplasie bénigne de la prostate (HBP). Nous avons étudié levieillissement prévu de cette population entre 2005 et 2018 afind’évaluer les besoins en soins urologiques.Méthodologie : À l’aide des projections démographiques de StatistiqueCanada, nous avons formulé des prévisions quant à la populationmasculine de 50 ans et plus entre 2005 et 2018; les résultatsde l’étude du comté d’Olmsted sur les symptômes urinaires nousont permis d’évaluer le nombre d’hommes de 50 ans et plus quidevraient présenter des symptômes modérés ou graves touchantles voies urinaires inférieures pendant la même période. Desdonnées de l’Institut canadien d’information sur la santé ont permisd’évaluer le nombre d’urologues en 2018.Résultats : Le nombre de Canadiens de 50 ans et plus devrait augmenterde 39,5 % entre 2005 et 2018, et le nombre d’hommesprésentant des symptômes modérés ou graves touchant les voiesurinaires inférieures, de 41,3 %. En revanche, le nombre d’urologuespratiquant en 2018 au Canada devrait être semblable aunombre établi en 2007 (soit 584). Pour que la hausse du nombred’urologues soit proportionnelle à la hausse du nombre d’hommesde 50 ans et plus qui présenteront des symptômes modérés ougraves touchant les voies urinaires inférieures, il faudrait que cenombre atteigne 799 en 2018.Conclusion : Il est peu probable que le nombre de médecins sespécialisant en urologie augmente. D’autres solutions doiventdonc être mises de l’avant afin de faire face au nombre croissantd’hommes âgés au prise avec des symptômes modérés ou gravestouchant les voies urinaires inférieures. La prise en charge initialede l’HBP incombe maintenant aux médecins de premiersrecours, mais ces derniers semblent considérer l’HBP comme unproblème de qualité de vie. Il est primordial que les urologuescollaborent étroitement avec les médecins de soins primaires pourassurer une prise en charge optimale des symptômes touchantles voies urinaires inférieures.

scholarly journals A Comparative Study of Efficacy and Safety Between Tamsulosin and Terazosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia

2016 ◽  
Vol 15 (1) ◽  
pp. 17-21
Author(s):  
Sakhawat Mahmud Khan ◽  
Md Matiar Rahaman Khan ◽  
Shahin Akhter ◽  
Md Mizanur Rahman
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Common Disease ◽  
Efficacy And Safety ◽  
College Hospital ◽  
Symptomatic Benign Prostatic Hyperplasia ◽  
Group A ◽  
Group B ◽  
A Prospective Study

Background: Lower urinary tract symptoms suggestive of symptomatic Benign Prostatic Hyperplasia (BPH) are a very common disease in elderly men .The incidence of benign prostatic hyperplasia is age related.Objectives: To compare the efficacy and safety of Tamsulosin and Terazosin in the treatment of symptomatic Benign Prostatic Hyperplasia.Methods: This was a prospective study carried out in the Department of Urology, Chittagong Medial College Hospital, Chittagong, Bangladesh during the period of July to December 2014. Total 40 patients of 45-80 years of age were consequently selected according to inclusion criteria. After completion of baseline clinical evaluation and investigations, participants were divided into two groups, group A and group B. Group A (n=20) was given Terazosin 1mg daily for 3 days at bed time and then 2 mg daily at bed time for 2 months. Group B (n=20) was given Tamsulosin, 0.4 mg per day for 2 months. Efficacy was evaluated of each group after 2 month follow up and lastly a comparison was made between them. The parameters monitored were International Prostate Symptoms Score (IPSS) Maximum urine flow rate (Qmax) and Post Voidal Residual Volume (PVR). Tamsulosin 0.4 mg and Terazosin 2 mg once daily for 8 weeks both are effective in relieving symptoms of BPH but Tamsulosin is superior to Terazosin in improvement of total IPSS (p<0.001) and Qmax (p<0.01) PVR (p<0.01) at the end point.Results: Outcome of parameters at follow up after 2 months. Tamsulosin group showed significant improvement of IPSS (p<0.05) PVR (p<0.001) and Qmax (p<0.001) than Terazosin. The incidence of adverse events by administration of Tamsulosin was less than that by Terazosin.Conclusion: Tamsulosin appears to have more efficacy and safety than Terazosin in symptomatic BPH.Chatt  Shi Hosp Med Coll J; Vol.15 (1); Jan 2016; Page 17-21

scholarly journals Role of alpha blockers and 7-days catheterization in enhancing the success of trial void in acute urinary retention due to benign prostatic hyperplasia: a double-blind randomized control trial

2018 ◽  
Vol 5 (10) ◽  
pp. 3256
Author(s):  
Rohit Garagadahalli Rangaiah ◽  
Vilvapathy Senguttuvan Karthikeyan
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Urinary Retention ◽  
Acute Urinary Retention ◽  
Primary Outcome Measure ◽  
Prostatic Hyperplasia ◽  
Double Blind ◽  
Alpha Blockers ◽  
Treatment Groups ◽  
First Time

Background: Acute urinary retention (AUR) in patients with benign prostatic hyperplasia (BPH) is common. This study evaluated the efficacy of three alpha-blockers with urethral catheterization for 7 days in trial without catheter (TWOC).Methods: This was a prospective, randomized, double-blind, active-control study conducted between November 2013 and May 2016. Patients aged more than 50 years, presenting with first-time painful AUR due to BPH were enrolled in this study. Eligible patients were randomized (1:1:1) to one of the three treatment groups to receive tamsulosin 0.4 mg, alfuzosin 10 mg or silodosin 8 mg for one week. The primary outcome measure was successful TWOC at 7 days.Results: A total of 118 patients were included in the study (tamsulosin, n=40; alfuzosin, n=38; and silodosin, n=40). The baseline parameters were comparable between the three groups. A total of 84 (71.2%) patients had successful TWOC at the end of 7 days (tamsulosin, n=30 (75%); alfuzosin, n=32 (84%); and silodosin, n=22 (55%)) and was significantly (p=0.015) different between three groups. Higher age, larger volume at retention and higher prostate volume were significantly (p<0.05) associated with the failure of TWOC.Conclusions: Results from this study demonstrate that there is a definite role of 7-day catheterization with alpha blockers in improving the rates of success of TWOC in men presenting with AUR due to BPH. The success of TWOC is multifactorial.

SNPs of Metabolic Syndrome are Associated with Benign Prostatic Hyperplasia Development and Progression in Chinese Population

2020 ◽  
Vol 15 ◽  
Author(s):  
Ding Xu ◽  
Xiaoling Lin ◽  
Xiaoqiang Qian ◽  
Jun Qi
Keyword(s):  
Metabolic Syndrome ◽  
Benign Prostatic Hyperplasia ◽  
Chinese Population ◽  
Systematic Investigation ◽  
Prostatic Hyperplasia ◽  
Common Disease ◽  
Clinical Parameters ◽  
Susceptibility Loci ◽  
Genetic Determinants ◽  
Elderly Men

Objective: Benign prostatic hyperplasia (BPH) is a common disease prevalent in elderly men but the genetic determinants of BPH is still remain unclear. Since metabolic syndrome, especially the diabetes, maybe influences the progression of benign prostatic hyperplasia, we investigated whether susceptibility loci for the diabetes would increase the risk of BPH development and progression in Chinese elderly men. Material and Methods: Fifteen SNPs associated with the diabetes risk in a Chinese population were genotyped in 377 BPH cases (152 aggressive and 225 non-aggressive BPH cases) and 1,008 controls. The association between the SNPs and risk of BPH development was evaluated through logistic regression. Additionally, effects of the 15 SNPs on BPH related clinical parameters, including body mass index (BMI) International Prostate Symptom Score (IPSS), Quality of Life (QoL) and prostate volume (PV) were also evaluated. Results: SNP rs9864104 in IGF2BP2 at 3q27 (OR=1.24, P =0.0148) was significantly associated with BPH development. In addition, SNP rs9863780, rs9864104, rs10229583 and rs17727841 were significantly associated with baseline clinical parameters in BPH patients. Moreover, the risk allele of rs6763887 (C) and rs17727841 (C) were significantly associated with the change of storage score and voiding score after treatment. No SNPs was associated with the risk of BPH progression. Conclusions: This is a systematic investigation on the contributions of diabetes susceptibility loci to risk of BPH development and progression. Our findings advance the understanding of the genetic basis of BPH and provide new insights into the genetic determinants shared between BPH and metabolic syndrome.

scholarly journals Effect and Mechanism of ShiZhiFang on Uric Acid Metabolism in Hyperuricemic Rats

2018 ◽  
Vol 2018 ◽  
pp. 1-11 ◽  
Author(s):  
Yansheng Wu ◽  
Yixing Wang ◽  
Jiaoying Ou ◽  
Qiang Wan ◽  
Liqiang Shi ◽  
...  
Keyword(s):  
Uric Acid ◽  
Serum Uric Acid ◽  
Blood Urea Nitrogen ◽  
Acid Metabolism ◽  
Group Model ◽  
Model Group ◽  
Urea Nitrogen ◽  
Treatment Groups ◽  
Anion Transporters ◽  
Gene And Protein Expression

Objective. To explore the effect and mechanism of ShiZhiFang on uric acid metabolism. Methods. 40 rats were divided into normal group, model group, ShiZhiFang group, and benzbromarone group. The hyperuricemic rat model was induced by yeast gavage at 15 g/kg and potassium oxonate intraperitoneal injection at 600 mg/kg for two weeks. During the next two weeks, ShiZhiFang group rats were given ShiZhiFang by gavage, and benzbromarone group rats were given benzbromarone by gavage. The serum uric acid, creatinine, blood urea nitrogen, XOD activity, urinary uric acid, urinary β2-MG, and histopathological changes were observed in the rats of each group after treatment. Results. The hyperuricemic model was established successfully and did not show the increase of serum creatinine and blood urea nitrogen. Compared with the model group, the serum uric acid, serum XOD activity, and urinary β2-MG were significantly decreased (p<0.05), and 24 h urinary uric acid excretion was significantly decreased (p<0.01) in ShiZhiFang group, whereas the two treatment groups were of no statistical significant in above indicators (p>0.05); renal histopathology showed that the lesions in two treatment groups were reduced compared to the model groups. The gene and protein expression of uric acid anion transporters rOAT1 and rOAT3 in the kidney was significantly higher than that in model group (p<0.01). Conclusion. The model is suitable for the study of primary hyperuricemia. The mechanisms of ShiZhiFang on uric acid metabolism in hyperuricemic rats may be involved in reducing the activity of serum XOD and promoting the transcription and expression of rOAT1 and rOAT3 in the kidney.

Sign in / Sign up

Export Citation Format

Share Document